Paclitero Injection – Uses, Strengths, Side Effects & FAQs

Paclitero Injection is an anticancer medicine containing paclitaxel, a chemotherapy agent belonging to the taxane class. It is used under specialist medical supervision to manage certain types of cancer. Paclitaxel works by interfering with the microtubules that cancer cells need to divide and multiply, helping slow or stop their growth.

Cordium Pharmaceuticals Pvt Ltd presents this product information to help healthcare professionals, pharmaceutical buyers and other interested readers understand Paclitero Injection, its therapeutic applications and important safety considerations.

Paclitero Injection: Available Strengths

Paclitero Injection is listed in different strengths and presentations, depending on the formulation and market. Reported presentations include:

Paclitero 100 mg Injection

Paclitero 260 mg Injection

Paclitero 300 mg Injection

Availability, vial volume, formulation and registration status may differ between countries. Always verify the product label, approved local prescribing information and current availability before placing an order or publishing a product specification.

Uses and Benefits of Paclitero Injection

Paclitero Injection may be prescribed for selected cancer indications, depending on the treatment protocol and local product approval.

1. Breast Cancer: Paclitaxel may be used alone or alongside other anticancer medicines to treat certain forms of breast cancer.

2. Ovarian Cancer: It may be included in chemotherapy regimens for selected patients with ovarian cancer.

3. Non-Small Cell Lung Cancer: Paclitaxel may form part of a combination chemotherapy regimen for eligible patients.

4. Other Approved Cancer Indications: Depending on the formulation, clinical circumstances and local approvals, paclitaxel-based treatments may be used for additional cancers.

The potential benefits include controlling cancer cell growth and helping manage disease progression. Treatment selection depends on the cancer type, stage, previous therapies, overall health and the treating oncologist’s assessment.

How Is Paclitero Injection Administered?

Paclitero Injection is administered intravenously by qualified healthcare professionals in an appropriate clinical setting. The dose, infusion schedule and treatment duration are determined by the oncologist according to the patient's condition, body measurements, laboratory results and prescribed treatment regimen. Patients should never self-administer this medicine.

Side Effects of Paclitero Injection

Paclitaxel can cause side effects, and their severity varies between patients. Common or clinically important adverse effects may include:

Nausea and vomiting

Hair loss

Fatigue and weakness

Reduced white blood cells, red blood cells or platelets

Numbness or tingling in the hands and feet

Muscle or joint pain

Diarrhoea or other digestive disturbances

Allergic or infusion-related reactions

Important safety information: Fever, unusual bleeding, breathing difficulties, severe allergic symptoms or signs of infection require prompt medical assessment. Regular blood tests and monitoring may be necessary during treatment.

Inform the treating team about existing medical conditions, pregnancy or breastfeeding, allergies and all medicines being taken. Paclitaxel treatment requires careful medical supervision because serious complications can occur.

Frequently Asked Questions (FAQs)

1. What is Paclitero Injection used for?

It is a paclitaxel-based chemotherapy medicine used for selected cancers, including certain breast, ovarian and non-small cell lung cancers.

2. What is the active ingredient in Paclitero Injection?

The active ingredient is paclitaxel. Check the individual product label to confirm the formulation and strength.

3. What strengths of Paclitero Injection are available?

Reported presentations include 30 mg, 100 mg, 260 mg and 300 mg. Confirm market-specific availability with the relevant authorised supplier.

4. Can Paclitero Injection cause hair loss?

Yes. Hair loss is a recognised potential side effect of paclitaxel treatment.

5. Is Paclitero Injection suitable for every cancer patient?

No. Its suitability depends on the diagnosis, treatment plan, laboratory results, medical history and the oncologist’s assessment.

6. Where can healthcare professionals obtain product information?

Contact Cordium Pharmaceuticals Pvt Ltd for relevant product documentation, subject to its confirmed supply arrangements, applicable regulatory requirements and destination-country approvals.

Conclusion

Paclitero Injection is a paclitaxel-based chemotherapy product used in specialist cancer care. Understanding its strengths, approved uses, potential adverse effects and administration requirements supports informed discussions between healthcare professionals and patients.

For accurate product specifications and market-specific regulatory information, consult the approved prescribing information and verify all detai